Boehringer Ingelheim Pharmaceuticals, Inc. vs Philips North America: FDA Enforcement Comparison

Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 2 for Boehringer Ingelheim Pharmaceuticals, Inc..

Boehringer Ingelheim Pharmaceuticals, Inc.: 0 warning letters, 2 recalls, 0 approval records, 0 Form 483s.

Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.

Side by side

Boehringer Ingelheim Pharmaceuticals, Inc. — Warning letters0

Philips North America — Warning letters0

Boehringer Ingelheim Pharmaceuticals, Inc. — Recalls2

Philips North America — Recalls355

Boehringer Ingelheim Pharmaceuticals, Inc. — Approval records0

Philips North America — Approval records0

Boehringer Ingelheim Pharmaceuticals, Inc. — Form 483s0

Philips North America — Form 483s0

Timeline

Boehringer Ingelheim Pharmaceuticals, Inc.

Most recent FDA action: July 8, 2026

Full history →

Philips North America

Most recent FDA action: July 1, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"Boehringer Ingelheim Pharmaceuticals, Inc. vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed August 29, 2026. https://argushq.ai/compare/boehringer-ingelheim-pharmaceuticals-inc-vs-philips-north-america

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗